Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Equity Average (2021 - 2025)

Amylyx Pharmaceuticals has reported Equity Average over the past 5 years, most recently at $318.6 million for Q4 2025.

  • Quarterly results put Equity Average at $318.6 million for Q4 2025, up 76.54% from a year ago — trailing twelve months through Dec 2025 was $318.6 million (up 76.54% YoY), and the annual figure for FY2025 was $235.0 million, down 21.43%.
  • Equity Average for Q4 2025 was $318.6 million at Amylyx Pharmaceuticals, up from $249.9 million in the prior quarter.
  • Over the last five years, Equity Average for AMLX hit a ceiling of $425.9 million in Q4 2023 and a floor of -$137.6 million in Q4 2021.
  • Median Equity Average over the past 5 years was $228.8 million (2024), compared with a mean of $204.9 million.
  • Biggest five-year swings in Equity Average: surged 672.19% in 2023 and later tumbled 57.62% in 2024.
  • Amylyx Pharmaceuticals' Equity Average stood at -$137.6 million in 2021, then skyrocketed by 276.08% to $242.3 million in 2022, then surged by 75.77% to $425.9 million in 2023, then tumbled by 57.62% to $180.5 million in 2024, then skyrocketed by 76.54% to $318.6 million in 2025.
  • The last three reported values for Equity Average were $318.6 million (Q4 2025), $249.9 million (Q3 2025), and $184.6 million (Q2 2025) per Business Quant data.